

| 货号 | PX-P5878 |
|---|---|
| 品牌 | ProteoGenix |
| 描述 |
Recombinant Human PCSK9 Protein, N-His (PX-P5878) expressed in E. coli, Purity: >90% as determined by SDS-PAGE..
Highlights
|
| 表达系统 | E. coli |
| Accession号 | Q8NBP7 |
| 蛋白长度 | Gln31-Gln692 |
| 应用 | ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress |
| 种属 | Homo sapiens (Human) |
| 性质 | Recombinant |
| 内毒素水平 | Please contact with the lab for this information. |
| 纯度 | >90% as determined by SDS-PAGE. |
| 预测分子量 | 73.35 kDa |
| 状态 | Lyophilized |
| 保存溶液 | Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| 重悬 | Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details. |
| 运输 | In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise. |
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 别名 | Proprotein convertase subtilisin/kexin type 9, Subtilisin/kexin-like protease PC9, NARC-1, PC9, Proprotein convertase 9, Neural apoptosis-regulated convertase 1, NARC1, PCSK9 |
| 背景 | Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a ~74 kDa protein. Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. PCSK9 is the therapeutic target of evolocumab (Repatha). 1. Poirier, S. et al. (2008) The Journal of biological chemistry 283, 2363-72. PMID: 18039658 2. Nassoury, N. et al. (2007) Traffic (Copenhagen, Denmark) 8, 718-32. PMID: 17461796 3. Fan, D. et al. (2008) Biochemistry 47, 1631-9. PMID: 18197702 4. Mayer, G. et al. (2008) The Journal of biological chemistry 283, 31791-801. PMID: 18799458 5. Chen, Y. et al. (2011) Biochemical and biophysical research communications 415, 515-8. PMID: 22074827 6. Jonas, MC. et al. (2008) EMBO reports 9, 916-22. PMID: 18660751 |
| Note | For research use only. |

24小时产品查询

扫一扫关注我们

专属渠道经理